Human Anterior gradient protein 2 homolog(AGR2) ELISA kit

Code CSB-EL001458HU
Size 96T,5×96T,10×96T
Trial Size 24T ELISA kits trial application
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Target Name anterior gradient homolog 2 (Xenopus laevis)
Alternative Names AG 2 ELISA Kit; AG 2 protein ELISA Kit; AG-2 ELISA Kit; AG2 ELISA Kit; AG2 protein ELISA Kit; AGR 2 ELISA Kit; AGR2 ELISA Kit; AGR2_HUMAN ELISA Kit; Anterior gradient 2 homolog (Xenopus laevis) ELISA Kit; anterior gradient 2 homolog ELISA Kit; Anterior gradient 2; protein disulphide isomerase family member ELISA Kit; Anterior gradient 2; Xenopus; homolog of ELISA Kit; Anterior gradient homolog 2 ELISA Kit; Anterior gradient protein 2 homolog ELISA Kit; Epididymis secretory protein Li 116 ELISA Kit; GOB 4 ELISA Kit; GOB4 ELISA Kit; HAG 2 ELISA Kit; hAG-2 ELISA Kit; hAG2 ELISA Kit; HAG2/R ELISA Kit; HEL S 116 ELISA Kit; HPC 8 ELISA Kit; hPC8 ELISA Kit; PDIA17 ELISA Kit; Protein disulfide isomerase family A member 17 ELISA Kit; secreted cement gland homolog ELISA Kit; Secreted cement gland protein XAG 2 homolog ELISA Kit; Secreted cement gland protein XAG-2 homolog ELISA Kit; Secreted cement gland protein XAG2 homolog ELISA Kit; XAG 2 ELISA Kit; XAG2 ELISA Kit
Abbreviation AGR2
Uniprot No. O95994
Species Homo sapiens (Human)
Sample Types serum, plasma, tissue homogenates
Detection Range 0.156 ng/mL-10 ng/mL
Sensitivity 0.039 ng/mL
Assay Time 1-5h
Sample Volume 50-100ul
Detection Wavelength 450 nm
Research Area Cancer
Assay Principle quantitative
Measurement Sandwich
Intra-assay Precision (Precision within an assay): CV%<8%
Three samples of known concentration were tested twenty times on one plate to assess.
Inter-assay Precision (Precision between assays): CV%<10%
Three samples of known concentration were tested in twenty assays to assess.
To assess the linearity of the assay, samples were spiked with high concentrations of human AGR2 in various matrices and diluted with the Sample Diluent to produce samples with values within the dynamic range of the assay.
1:1Average %97
Range %92-104
1:2Average %101
Range %95-110
1:4Average %92
Range %88-96
1:8Average %85
Range %80-90
The recovery of human AGR2 spiked to levels throughout the range of the assay in various matrices was evaluated. Samples were diluted prior to assay as directed in the Sample Preparation section.
Sample TypeAverage % RecoveryRange
Serum (n=5) 9490-100
EDTA plasma (n=4)8781-91
Typical Data
These standard curves are provided for demonstration only. A standard curve should be generated for each set of samples assayed.
ng/ml OD1OD2AverageCorrected
102.501 2.427 2.464 2.296
51.943 2.075 2.009 1.841
2.51.427 1.462 1.445 1.277
1.250.901 0.945 0.923 0.755
0.6250.610 0.584 0.597 0.429
0.3120.411 0.430 0.421 0.253
0.1560.291 0.304 0.298 0.130
00.165 0.171 0.168
and FAQs
Storage Store at 2-8°C. Please refer to protocol.
Lead Time 7-14 working days

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Earn $30 Amazon Card or 20μL/μg CUSABIO Trial Size Antibody. Details of rewards >>

Target Data

Function Required for MUC2 post-transcriptional synthesis and secretion. May play a role in the production of mucus by intestinal cells (By similarity). Proto-oncogene that may play a role in cell migration, cell differentiation and cell growth. Promotes cell adhesion
Gene References into Functions
  1. AGR2 silencing could promote cell apoptosis and inhibit cell migration, invasion and chemotherapy resistance of pancreatic cancer cells with the involvement of the ERK/AKT axis PMID: 30055941
  2. Serum AGR2 can be used as a serum marker for clinical prognosis of nasopharyngeal carcinoma. However, serum AGR2 levels could not provide advantages in clinical practice for the differential diagnosis of cancer. PMID: 29269202
  3. The results suggest that MUC13 overexpression and loss of expression of AGR2 may predict the progression of Intraductal papillary mucinous neoplasm and an unfavorable prognosis in patients with Intraductal papillary mucinous neoplasm PMID: 29650332
  4. Cytosolic AGR2 contributed to cell metastasis ascribed to its stabilizing effect on p65 protein, which subsequently activated the NF-kappaB and facilitated epithelial to mesenchymal transition (EMT). PMID: 29410027
  5. Our data confirm AGR2 as a keeper of epithelial phenotypes, showing a positive role of AGR2 in the regulation of the epithelial marker E-cadherin and a negative effect on the mesenchymal markers vimentin and N-cadherin. PMID: 28810836
  6. Authors demonstrated that inhibition of either FOXM1 or AGR2 in human PIMAs inhibited mucinous characteristics, and reduced tumor growth and invasion. FOXM1 is necessary and sufficient to induce mucinous phenotypes in lung tumor cells in vivo. PMID: 29267283
  7. AGR2 is secreted by prostate cancer cells and induces programmed cell death in normal cells PMID: 27283903
  8. secretion and cell surface localization of AGR2 are characteristic of bladder cancer, while expression of AGR2 by itself is not. PMID: 26894971
  9. Obesity induces the expression of the mitochondrial form of arginase ARG2 in pancreatic ductal adenocarcinoma. PMID: 28808255
  10. Overexpression of AGR2 counteracts the phenotypes induced by miR-342-3p. PMID: 29107102
  11. The authors conclude that extracellular AGR2 plays an extracellular role independent of its endoplasmic reticulum function and elucidate this gain-of-function as a novel and unexpected critical extracellular matrix microenvironmental pro-oncogenic regulator of epithelial morphogenesis and tumorigenesis. PMID: 27240165
  12. High AGR2 expression is associated with ovarian cancer. PMID: 28481872
  13. This study demonstrates that AGR2, which is overexpressed in a variety of human cancers and provides a poor prognosis, up-regulates DUSP10 which subsequently inhibits p38 MAPK and prevents p53 activation by phosphorylation. PMID: 26733232
  14. A direct impact of mTOR signalling on AGR2 3'UTR shortening associated with increased protein synthesis was found, which led to the identification of a novel molecular mechanism involved in upregulation of AGR2 levels in mTOR-activated cells via modulating the 3'UTR length of AGR2 mRNA. PMID: 28408318
  15. Suggest elevated AGR2 as a candidate tamoxifen-dependent mechanism of action responsible for increased incidence of endometrial cancer. PMID: 28402678
  16. AGR2 could also be upregulated in hormone-independent manner. AGR2 expression was shown to be significantly increased in HER2 positive breast tumors on both the mRNA and the protein level. PMID: 28238761
  17. Our findings demonstrated recombinant human endostatin-gold nanoparticles might normalize vessels by interfering anterior gradient 2-mediated angiogenesis in metastatic colorectal cancer. PMID: 28714365
  18. All these data clearly showed that anterior gradient protein 2 is highly expressed in breast cancer and can be regarded as a putative biomarker for breast cancer prognosis. PMID: 28671019
  19. AGR2, through interaction with ER-alpha, enhances fulvestrant resistance and IGF-1-induced carcinogenesis in breast cancer cells. PMID: 27063095
  20. AGR2 inhibits TNF-alphainduced Caco-2 cell hyperpermeability by regulating TJ and that this protective mechanism may be promoted by inhibition of NF-kappaB p65-mediated activation of the MLCK/p-MLC signaling pathway. PMID: 28339048
  21. our study showed the important role of AGR2 in regulating EMT of glioblastoma. SDF-1 signaling induced the expression of AGR2 to control the progress of EMT in the progression of glioblastoma. PMID: 26608373
  22. Results show that AGR2 is O-glycosylated upon secretion from human and rat cell lines, and that this form of the protein is released from healthy cells and not as a result of cell lysis. PMID: 26169982
  23. Nearly all NSCLC tumors show AGR2 expression. Lung cancer expression of AGR2 has prognostic value for younger patients. PMID: 26445321
  24. These data together identify the single cysteine of AGR2 as an oxidant responsive moiety that regulates its propensity for oxidation and its monomeric-dimeric state. PMID: 26876500
  25. The prognostic impact of AGR2 expression could be related to treatment outcome in estrogen receptor-positive breast cancers and/or its metastasis-promoting effects. PMID: 25663596
  26. analysis of molecular characteristics, function, and regulation of AGR2 in cancer[review] PMID: 25937245
  27. AGR2 was higher in HNSCC than in normal oral mucosa. High levels were associated with the T category, pathological grade and lymphatic metastasis. AGR2 expression increased in recurring HNSCC after radiotherapy or cisplatin-based chemotherapy. PMID: 25871396
  28. The mechanism linking the IGF-1/insulin signal and AGR2 promoter activation is important. PMID: 25956506
  29. Data show the potential usability of anterior gradient homolog 3 (AGR3) and anterior gradient homolog 2 (AGR2) as biomarkers for blood-based early detection of breast cancer. PMID: 25875093
  30. Our findings, for the first time, describe AGR2 as an important regulator in chemical hypoxia-induced doxorubicin resistance in breast cancer cells PMID: 26079208
  31. Relying on available data and in silico analyses, study shows that AGR2 and AGR3 proteins are co-expressed or uncoupled in context-dependent manners in diverse carcinomas and healthy tissues. PMID: 25666661
  32. High AGR2/LGR5 was associated with poor progression-free survival by multivariate analysis. PMID: 22605983
  33. Data define the importance of AGR2 in breast cancer cell growth and highlight a mechanism where changes in FOXA1 activity obviate the need for ER in the regulation of this gene. PMID: 25100862
  34. Knockdown of anterior gradient 2 expression extenuates tumor-associated phenotypes of SNU-478 ampulla of Vater cancer cells. PMID: 25367337
  35. AGR2 is a novel marker of papillary thyroid carcinoma. PMID: 24976026
  36. AGR2 splice variant transcripts are potential diagnostic biomarkers for the non-invasive detection of PCa using urine exosomes. PMID: 25237833
  37. Expression of anterior gradient 2 is decreased with the progression of human biliary tract cancer. PMID: 25186196
  38. AGR2 has both intracellular and extracellular effects in the intestine PMID: 25111734
  39. Anterior gradient 2 downregulation in a subset of pancreatic ductal adenocarcinoma is a prognostic factor indicative of epithelial-mesenchymal transition. PMID: 25418581
  40. Results indicate that DNA methylation within the AGR2 promoter modulates more aggressive cancer cell phenotypes. PMID: 24920423
  41. Data demonstrates that AGR2 protein has a more dominant action on proteome remodelling rather than transcriptome effects and highlight a dominant effect on p53 pathway attenuation. PMID: 24710632
  42. anterior gradient 2 (AGR2) was overexpressed in human Nasopharyngeal carcinoma (NPC) tissues, particularly in cervical lymph node metastatic nasopharyngeal carcinoma. PMID: 24717913
  43. On the basis of an initial cohort of 37 subjects, urinary AGR2/PSA concentration ratios showed a significant difference (P = 0.026) between noncancer and cancer PMID: 24251762
  44. These data suggest that AGR-2 influence prostate cancer metastasis by regulation of cellular adhesion and apoptosis. PMID: 24587138
  45. AGR2-mediated lung adenocarcinoma metastasis novel mechanism network through repression with interferon coupling cytoskeleton to steroid metabolism-dependent humoral immune response. PMID: 24960290
  46. Increased expression of the AGR2 and ERp57 is associated with cancer. [review] PMID: 24490732
  47. Data indicate that aberrantly elevated anterior gradient 2 (AGR2) expression predicts poor patient outcome. PMID: 24177142
  48. AGR2 is frequently lost in colorectal carcinomas and might be a novel independent prognostic factor for overall patient survival. PMID: 24794000
  49. Prostate cancer biomarkers, AGR2 and CD10, can be used in combination to stratify prostate cancer patients for clinical outcome. PMID: 23348903
  50. overexpression of AGR2 showed a positive correlation with oral tumor metastasis. PMID: 23834814

Show More

Hide All

Subcellular Location Secreted, Endoplasmic reticulum
Protein Families AGR family
Tissue Specificity Expressed strongly in trachea, lung, stomach, colon, prostate and small intestine. Expressed weakly in pituitary gland, salivary gland, mammary gland, bladder, appendix, ovary, fetal lung, uterus, pancreas, kidney, fetal kidney, testis, placenta, thyroid
Database Links

HGNC: 328

OMIM: 606358

KEGG: hsa:10551

STRING: 9606.ENSP00000391490

UniGene: Hs.530009


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2021 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1